STOCK TITAN

Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that its CEO, Mel Sorensen, M.D., will present at the BofA Securities 2021 Virtual Healthcare Conference on May 12, 2021, at 8:45 a.m. ET. The presentation can be viewed live on the company's Investors page, with an archived version available for 30 days post-event.

Galera is focused on innovative therapeutics for cancer treatment, notably avasopasem manganese (GC4419), aimed at reducing severe oral mucositis from radiotherapy. Various clinical trials are ongoing to evaluate its effectiveness in multiple cancer types.

Positive
  • None.
Negative
  • None.

MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021, at 8:45 a.m. ET.

A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer. Galera also intends to initiate the GRECO-2 Phase 2b trial of GC4711 in combination with SBRT in patients with LAPC. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com

William Windham
Solebury Trout
646-378-2946
wwindham@soleburytrout.com  

Media Contact:
Zara Lockshin
Solebury Trout
646-378-2960
zlockshin@soleburytrout.com


FAQ

When is the BofA Securities 2021 Virtual Healthcare Conference presentation by Galera Therapeutics?

Mel Sorensen, CEO of Galera Therapeutics, will present on May 12, 2021, at 8:45 a.m. ET.

How can I watch the Galera Therapeutics presentation at the BofA Securities conference?

The presentation will be available live on Galera's Investors page, with an archived version accessible for 30 days after the event.

What is Galera Therapeutics' lead product candidate?

Galera's lead product candidate is avasopasem manganese (GC4419), designed to reduce radiation-induced severe oral mucositis.

What clinical trials is Galera Therapeutics currently conducting?

Galera is conducting trials, including the Phase 3 ROMAN trial for avasopasem in head and neck cancer patients and other trials targeting lung cancer and COVID-19.

What designations has the FDA granted to Galera's avasopasem?

Avasopasem has received Fast Track and Breakthrough Therapy designations from the FDA for reducing severe oral mucositis.

GALERA THERAPEUTICS INC

OTC:GRTX

GRTX Rankings

GRTX Latest News

GRTX Stock Data

6.52M
54.39M
31.63%
1.07%
3.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MALVERN